Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L W King

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Surgical Neurology|March 1, 1983
Cavernous sinus syndrome due to prolactinoma: resolution with bromocriptineL W King, M E Molitch, J W Gittinger, et al.
Journal of Endocrinological Investigation|October 1, 1984
Twenty-four-hour prolactin secretory patterns in women with galactorrhea, normal menses, normal random prolacting levels and abnormal sellar tomogramsL P Kapcala, M E Molitch, J Arno, et al.
Circulation|January 1, 1996
The protective dose of the potent GPIIb/IIIa antagonist SC-54701A is reduced when used in combination with aspirin and heparin in a canine model of coronary artery thrombosisL G Frederick, O D Suleymanov, L W King, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 1, 1993
SC-49992, a mimetic of the peptide arginine-glycine-aspartic acid-phenylalanine that blocks platelet aggregation, enhances recombinant tissue plasminogen activator-induced thrombolysis and prevents reocclusion in a canine model of coronary artery thrombosisL P Feigen, N S Nicholson, L W King, et al.
The Journal of Clinical Endocrinology and Metabolism|December 1, 1982
Surgical cure of prolactinoma reverses abnormal prolactin repsonse to carbidopa/L-dopaM E Molitch, R H Goodman, K D Post, et al.
Circulation|September 4, 1998
Protective effect of oral xemilofiban in arterial thrombosis in dogs: increased activity in combination with aspirinL G Frederick, O D Suleymanov, J A Szalony, et al.
Thrombosis Research|June 1, 1994
SC-49992--a potent and specific inhibitor of platelet aggregationN S Nicholson, S G Panzer-Knodle, L W King, et al.
Thrombosis Research|June 1, 1991
In vitro and in vivo effects of a peptide mimetic (SC-47643) of RGD as an antiplatelet and antithrombotic agentN S Nicholson, S G Panzer-Knodle, A K Salyers, et al.
Circulation|January 15, 1995
SC-54684A: an orally active inhibitor of platelet aggregationN S Nicholson, S G Panzer-Knodle, A K Salyers, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 1, 1991
Antiplatelet and antithrombotic effects of platelet glycoprotein IIb/IIIa (GPIIb/IIIa) inhibition by arginine-glycine-aspartic acid-serine (RGDS) and arginine-glycine-aspartic acid (RGD) (O-me)Y (SC-46749)N S Nicholson, S G Panzer-Knodle, A K Salyers, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Surgical Neurology|March 1, 1983
Cavernous sinus syndrome due to prolactinoma: resolution with bromocriptineL W King, M E Molitch, J W Gittinger, et al.
Journal of Endocrinological Investigation|October 1, 1984
Twenty-four-hour prolactin secretory patterns in women with galactorrhea, normal menses, normal random prolacting levels and abnormal sellar tomogramsL P Kapcala, M E Molitch, J Arno, et al.
Circulation|January 1, 1996
The protective dose of the potent GPIIb/IIIa antagonist SC-54701A is reduced when used in combination with aspirin and heparin in a canine model of coronary artery thrombosisL G Frederick, O D Suleymanov, L W King, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 1, 1993
SC-49992, a mimetic of the peptide arginine-glycine-aspartic acid-phenylalanine that blocks platelet aggregation, enhances recombinant tissue plasminogen activator-induced thrombolysis and prevents reocclusion in a canine model of coronary artery thrombosisL P Feigen, N S Nicholson, L W King, et al.
The Journal of Clinical Endocrinology and Metabolism|December 1, 1982
Surgical cure of prolactinoma reverses abnormal prolactin repsonse to carbidopa/L-dopaM E Molitch, R H Goodman, K D Post, et al.
Circulation|September 4, 1998
Protective effect of oral xemilofiban in arterial thrombosis in dogs: increased activity in combination with aspirinL G Frederick, O D Suleymanov, J A Szalony, et al.
Thrombosis Research|June 1, 1994
SC-49992--a potent and specific inhibitor of platelet aggregationN S Nicholson, S G Panzer-Knodle, L W King, et al.
Thrombosis Research|June 1, 1991
In vitro and in vivo effects of a peptide mimetic (SC-47643) of RGD as an antiplatelet and antithrombotic agentN S Nicholson, S G Panzer-Knodle, A K Salyers, et al.
Circulation|January 15, 1995
SC-54684A: an orally active inhibitor of platelet aggregationN S Nicholson, S G Panzer-Knodle, A K Salyers, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 1, 1991
Antiplatelet and antithrombotic effects of platelet glycoprotein IIb/IIIa (GPIIb/IIIa) inhibition by arginine-glycine-aspartic acid-serine (RGDS) and arginine-glycine-aspartic acid (RGD) (O-me)Y (SC-46749)N S Nicholson, S G Panzer-Knodle, A K Salyers, et al.
Pageof 2